Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals... Show more
Zoetis remains the world's largest pure-play animal health company, spun off from Pfizer in 2013 and led by CEO Kristin Peck. Its revenue mix skews roughly 70% toward companion animals and 30% toward livestock, with the United States contributing about 55% of sales and companion-animal products comprising about 80% of the U.S. business. That concentration explains much of the current pressure: its marquee franchises — Apoquel (dermatology), Simparica and Simparica Trio (parasiticides), and Librela and Solensia (osteoarthritis, or OA, pain therapies) — face new competitive entrants, aggressive promotional activity, and some generic incursions.
The medium-term positioning story, however, is one of diversification. Zoetis is expanding its diagnostics platform through acquisitions such as VitalRADS (veterinary teleradiology) and Neogen's animal genomics business, and it is pushing deeper into international and emerging markets. The company has also reorganized its U.S. go-to-market structure to place more veterinarians in front of customers, supporting its shift toward specialty, chronic, and monoclonal antibody (mAb) products, which are engineered proteins designed to target specific disease pathways. Its scale, direct-to-veterinarian reach, and research and development (R&D) engine remain structural advantages, even as near-term pricing power and market share face challenges.
The most immediate catalyst is the third-quarter 2026 earnings release on November 5, 2026. Beyond the headline results, investors will scrutinize commentary on whether U.S. clinic visits are stabilizing and whether gross-to-net pricing investments are easing. Management has signaled that competitive intensity and pet-owner price sensitivity — particularly among younger Gen Z and millennial owners — weighed on therapeutic visits and doses.
Longer term, the pipeline is the central catalyst. Zoetis has stated an expectation of at least one major market approval annually in coming years. Notable launches include Lenvia in Canada and Portela in Europe for OA pain, with U.S. approval for Lanivia anticipated around 2027. The company also points to a roughly $5 billion market opportunity across chronic kidney disease, oncology, and cardiology in dogs and cats. Diagnostics launches, including the Vetscan OmniMax platform, add a recurring-revenue element that could improve earnings quality.
Analyst ratings reflect the reset in expectations. The consensus recommendation has drifted from Buy toward Hold, with the average price target near $88 — modestly above recent trading levels — and a wide dispersion from roughly $74 to $115. Notable 2026 actions include downgrades and repeated target reductions, indicating that Wall Street is more cautious than optimistic about the pace of recovery.
Zoetis sits at the intersection of consumer discretionary spending and structural pet-care demand. Higher interest rates and lingering inflation have pressured household budgets, prompting some pet owners to defer non-urgent veterinary visits or trade down on premium treatments. This consumer sensitivity directly affects the dermatology, parasiticide, and OA pain franchises that anchor U.S. revenue.
Offsetting these headwinds, the global animal protein complex remains a tailwind. Livestock demand — cattle, poultry, swine, and aquaculture — has grown at a mid-to-high-single-digit pace, supported by rising protein consumption and vaccine adoption. Technology adoption is another macro driver: the veterinary industry's gradual embrace of diagnostics, genomics, and AI-assisted discovery favors a company with Zoetis's data assets, including its Basepaws genetics database. Regulatory developments, such as the emergency use authorization for Simparica Trio against New World screwworm, illustrate how animal-health policy can open new demand pockets.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders gauge whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the coming week or month. It is built to help users spot developing trends, evaluate possible breakouts or reversals, and compare predictions across a broad range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors tracking evolving setups like Zoetis, the Trend Prediction Engine offers a structured, data-driven way to monitor directional signals alongside fundamental research.
Looking into 2026 and beyond, the central question is whether Zoetis can transition from a growth reset to a growth re-acceleration. Management's full-year 2026 guidance implies organic revenue contraction, but its long-term narrative rests on structural themes: the "premiumization" of pet care, rising global pet ownership, and the medicalization of companion-animal treatment in international markets where penetration still lags the United States.
Margin sustainability will depend on execution. The company has launched cost and productivity programs and continues to return capital through a growing dividend (currently $0.53 per share quarterly) and share repurchases, which could support earnings per share (EPS) even in a low-growth environment. Capital allocation toward diagnostics and genomics acquisitions suggests a deliberate pivot toward recurring, data-driven revenue streams.
Competitive threats remain the principal wild card. If rivals sustain promotional pricing in dermatology and parasiticides, Zoetis's premium positioning could face continued pressure. Conversely, evidence of differentiated efficacy — such as peer-reviewed data showing Simparica Trio's superiority against resistant heartworm — could help defend share. Consensus expectations are subdued, with analysts modeling only low-single-digit revenue and earnings growth in the near term; any stabilization in U.S. franchise sales or upside from pipeline launches would likely be viewed favorably by the market.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with PAHC. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then PAHC could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | -1.08% | ||
| PAHC - ZTS | 58% Loosely correlated | -0.29% | ||
| ELAN - ZTS | 47% Loosely correlated | -2.12% | ||
| PBH - ZTS | 36% Loosely correlated | +0.46% | ||
| SNDL - ZTS | 33% Loosely correlated | N/A | ||
| AMPH - ZTS | 33% Poorly correlated | -0.24% | ||
More | ||||
| Ticker / NAME | Correlation To ZTS | 1D Price Change % |
|---|---|---|
| ZTS | 100% | -1.08% |
| Pharmaceuticals: Generic industry (81 stocks) | 0% Poorly correlated | -0.07% |
a pet medication company
Industry PharmaceuticalsGeneric
ZTS saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 53 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 59%.
The 10-day moving average for ZTS crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 44%.
Following a +1.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZTS advanced for three days, in 145 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.
The Aroon Indicator entered an Uptrend today. In 92 of 178 cases where ZTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
The 10-day RSI Indicator for ZTS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 10 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 59%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 62 cases where ZTS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
The Moving Average Convergence Divergence Histogram (MACD) for ZTS turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 29 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
ZTS broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is 18 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. ZTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.422) is normal, around the industry mean (6.379). P/E Ratio (12.953) is within average values for comparable stocks, (0.548). ZTS's Projected Growth (PEG Ratio) (6.647) is slightly higher than the industry average of (2.202). Dividend Yield (0.027) settles around the average of (0.062) among similar stocks. P/S Ratio (3.299) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.